Skip to main content

Table 3 Patient characteristics according to the glomerular filtration rate and urinary albumin creatinine ratio

From: Impact of chronic kidney disease on the prevalence of cardiovascular disease in patients with type 2 diabetes in Spain: PERCEDIME2 study

Variables Values eGFR (nm)/ eGFR (nm)/ eGFR ↓/ eGFR ↓/ P value UACR↑ vs P value eGFR ↓ vs
UACR(nm) UACR ↑ UACR (nm) UACR ↑ UACR(nm) eGFR (nm)
N 1141 674 85 311 69 154 vs 987 380 vs 761
Age (years) (SD) 66.8 (11.3) 63.7 (11.0) 64.3 (10.2) 72.4 (9.3) 74.1 (9.7) 0.048 <0.001
Gender (men,%) 691 (60.6) 345 (51.0) 44 (48.2) 254 (81.7) 51 (73.9) 0.823 <0.001
T2DM Duration (years) (SD) 9.1 (6.7) 8.4 (6.4) 8.7 (6.3) 9.6 (6.5) 12.6 (8.1) 0.007 <0.001
BMI (kg/m2) (SD) 30.3 (5.2) 30.5 (5.4) 31.2 (5.4) 29.3 (4.5) 30.9 (5.6) 0.058 0.004
BMI ≥30 kg/m2 (%) 529 (46.4) 327 (48.4) 45 (52.9) 126 (40.5) 31 (44.9) 0.424 0.016
Waist circumference (cm) (SD) 100.0 (17.1) 99.8 (16.8) 100.4 (17.5) 99.0 (18.3) 103.6 (16.1) 0.118 0.514
HbA1c mean (SD) 7.3 (1.3) 7.3 (1.3) 7.8 (1.5) 7.1 (1.2) 7.5 (1.1) <0.001 0.052
Smoking n (%)       0.467 <0.001
  Current 158 (13.8) 96 (14.2) 18 (21.2) 37 (11.9) 7 (10.1)   
  Past-smoker 334 (29.3) 164 (24.3) 22 (25.9) 122 (39.2) 26 (37.7)   
  Never 649 (56.9) 416 (61.5) 45 (52.9) 152 (48.9) 36 (52.2)   
Insulin n (%) 281 (24.6) 159 (23.5) 26 (30.6) 65 (20.9) 31 (44.9) <0.001 0.725
Oral antidiabetic agents n (%) 965 (84.6) 586 (86.7) 77 (90.6) 249 (80.1) 53 (76.8) 0.953 0.001
Oral antidiabetic agents + insulin n (%) 210 (18.4) 124 (18.3) 23 (27.1) 43 (13.8) 20 (29.0) 0.001 0.261
Hyperlipidemia n (%) 773 (67.7) 228 (33.7) 22 (25.9) 93 (29.9) 25 (36.2) 0.621 0.540
Hypertension n (%) 849 (74.4) 465 (68.8) 68 (80.0) 255 (82.0) 61 (88.4) 0.004 <0.001
Antihypertensive treatment n (%) 866 (75.9) 466 (68.9) 74 (87.1) 263 (84.6) 63 (91.3) <0.001 <0.001
Systolic Blood Pressure (mmHg) (SD) 134.5 (13.2) 134.0 (35.4) 137.8 (14.9) 134.4 (12.8) 136.9 (16.4) 0.018 0.539
Diastolic Blood Pressure (mmHg) (SD) 77.0 (9.1) 78.1 (8.8) 78.2 (9.3) 74.7 (9.2) 74.8 (9.8) 0.892 <0.001
Cholesterol total (mmol/L) (SD) 183.7 (37.2) 186.9 (36.8) 189.1 (41.4) 177.0 (35.8) 176.2 (37.9) 0.853 <0.001
Cholesterol HDL (mmol/L) (SD) 135.7 (35.9) 137.4 (35.4) 142.8 (41.4) 131.2 (35.0) 131.0 (35.9) 0.514 0.004
Cholesterol LDL (mmol/L) (SD) 107.9 (32.1) 110.5 (35.4) 109.2 (33.5) 103.8 (31.6) 99.6 (33.2) 0.211 <0.001
Cholesterol non HDL (mmol/L) (SD) 48.0 (13.5) 49.5 (13.3) 46.2 (11.5) 45.8 (13.8) 45.7 (13.7) 0.055 <0.001
Tryglicerides (mmol/L) (SD) 151.3 (92.2) 146.4 (88.8) 177.3 (105.4) 146.8 (71.6) 188.4 (157.0) <0.001 0.296
Lipid-lowering therapy n, (%) 738 (64.7) 413 (61.1) 60 (70.6) 215 (69.1) 50 (72.5) 0.060 0.012
Plasmatic creatinina (mg/dl) (SD) 0.92 (0.3) 0.78 (0.13) 0.78 (0.14) 1.17 (0.23) 1.31 (0.45) <0.001 <0.001
Glomerular filtration ratio, mL/min/1,73 m2 (SD) 75.6 (26.1) 89.8 (19.7) 88.3 (19.9) 48.5 (9.1) 43.6 (10.6) <0.001 <0.001
Urine albumin-creatinine ratio (mg/g) (SD) 20,9 (42,2) 7.2 (5.9) 96.7 (61.3) 8.0 (6.7) 119.8 (70.1) <0.001 0.002
Coronary heart disease (%) 163 (14.3) 67 (9.9) 9 (10.6) 68 (21.9) 19 (27.5) 0,137 <0.001
Peripheral arterial disease (%) 91 (8.0) 32 (4.7) 8 (9.4) 33 (10.6) 18 (26.1) <0.001 <0.001
Stroke (%) 72 (6.3) 31 (4.6) 5 (5.9) 29 (9.3) 7 (10.1) 0.416 0.002
  1. p-value bettween interactions low eGFR and albuminuria,> 0.05 in all cases.
  2. nm: normal; eGFR: estimated glomerular filtration rate according to CKD-EPI in mL/min/1.73 m2; UACR: urinary albumin creatinin rate in mg/gr; BMI: body mass index.